regorafenib lengthens suvival in colorectal cancer with kras mutation
Published 12 years ago • 1.3K plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
5:52
asco 2012: three drugs for colorectal cancer
-
2:17
sotorasib plus panitumumab in kras-mutated colorectal cancer | nejm
-
0:58
managing colorectal cancer in patients who progress on regorafenib
-
3:56
panitumumab
-
9:34
regorafenib in colorectal cancer
-
1:04
marwan g. fakih, md, on combining regorafenib checkpoint inhibition in advanced crc
-
3:53
regorafenib in colorectal cancer: optimizing the dose
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
3:46
targeting colorectal cancer: kras and nras mutations
-
8:26
regorafenib in advanced colorectal cancer: dosing strategies
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:30
dr. nancy l. lewis discusses the correct trial for regorafenib in metastatic colorectal cancer
-
1:04
exploring regorafenib and nivolumab as treatment for colorectal cancer
-
3:54
colorectal cancer: patient follow-up with regorafenib
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
1:47
dr. jordi bruix on the impact regorafenib will have on liver cancer treatment
-
0:58
dr. kim reviews studies investigating regorafenib in mcrc
-
1:08
first-line durvalumab monalizumab in microsatellite-stable crc